Unlike traditional dandruff products that focus on a single symptom, Denorex Multi-Symptom is the only dandruff solution built around a multi-symptom approach Most people dealing with dandruff aren’t ...

A team of leading clinical research scientists from the Departments of Psychiatry and Dermatology at the Icahn School of Medicine at Mount Sinai has found that the serum of patients with major ...

For people living with atopic dermatitis, the real test of any new therapy is not what it can do in a few months, but whether it can keep angry, inflamed skin quiet over the long haul. Nektar ...

Almirall SA has submitted a CTA filing for a bispecific antibody targeting IL-13 and OX-40L for the treatment of atopic dermatitis. The company expects to initiate a first-in-human phase I trial ...

The percentage of patients achieving total clearance of eczema lesions in a Phase 2b trial increased with prolonged rezpeg treatment.

The Phase IIa trial of EVO301 showed similar EASI reduction to Sanofi’s flagship AD drug Dupixent.

Evommune surged 70% after EVO301's Phase 2a data showed rapid, significant EASI reductions in moderate-to-severe atopic ...

Nektar Therapeutics stock surged after positive data showed sustained and deepening disease control with its eczema therapy.

In what has turned out to be an important day for the atopic dermatitis community, shares of two biopharma companies surged on phase II data showing statistically significant and sustained outcomes ...

Nektar Therapeutics today announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of rezpegaldesleukin, a novel regulatory T-cell (Treg) biologic, in ...

The newly public Evommune shared data showing that EVO301, an IL-18 targeting protein, cleared symptoms comparably to Regeneron and Sanofi’s mega-blockbuster in a mid-stage atopic dermatitis clinical ...

With Incyte losing patent protection for blood cancer standout Jakafi in late 2028, the Delaware-based company will have to rely more on its topical cream Opzelura. | With Incyte set to lose patent ...